R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
View original at globenewswire.comR1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
We are delighted to partner with R1 Therapeutics to develop AP306 globally and improve outcomes for the millions of CKD patients struggling with inadequate phosphate control
60% confidenceUncontrolled hyperphosphatemia contributes to bone and cardiovascular disease, leading to significant risk of morbidity and mortality
60% confidenceCurrent phosphate binders, which have been the standard of care for 60 years, are limited by low binding capacity, high pill burden and poor gastrointestinal tolerability, contributing to poor adherence and limiting the effectiveness of these therapies
60% confidenceAP306 represents a fundamentally new approach to treating hyperphosphatemia. By blocking the active transport of phosphate through three different phosphate transporters in the GI tract, initial clinical studies suggest AP306 has the potential to deliver superior efficacy with substantially lower pill burden compared to current phosphate binder therapies
60% confidenceWe are excited to be launching R1 Therapeutics in partnership with Alebund and with support from a strong, experienced syndicate including DaVita and U.S. Renal Care, recognized global providers transforming kidney care
60% confidenceR1 Therapeutics brings together an exceptional leadership team with deep nephrology expertise and a clear vision for advancing AP306. This asset addresses a significant unmet need in a large, underserved patient population
60% confidenceIf successful, AP306 should redefine the class of phosphate lowering therapies and become the treatment of choice for the management of hyperphosphatemia
60% confidenceMore than 500,000 patients in the United States and four million worldwide receive dialysis, however more than 40% of US patients fail to achieve treatment targets
60% confidenceAP306 is the only agent that blocks the active transport of phosphate for the treatment of CKD
60% confidence